{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-025491","form_type":"8-K","ticker":"DARE","cik":"0001401914","company_name":"Dare Bioscience, Inc.","filed_at":"2025-12-01T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.313938+00:00","generated_at":"2026-05-16T15:52:06.976551+00:00","sec_items":["1.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Bayer terminates Ovaprene license; Daré regains full rights, Phase 3 study continues","bullets":["Bayer HealthCare terminated Ovaprene license agreement effective Feb 24, 2026 due to strategic prioritization.","Daré regains full commercialization rights to Ovaprene, a hormone-free monthly intravaginal contraceptive.","Pivotal Phase 3 study continues with positive interim data (July 2025) and Gates Foundation grant support.","Enrollment expected to complete in 2026; no change to timelines or operations.","Daré to explore partnerships and strategic transactions for Ovaprene."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-025491","json":"https://secwatch.observer/filing/0001493152-25-025491.json","markdown":"https://secwatch.observer/filing/0001493152-25-025491.md","text":"https://secwatch.observer/filing/0001493152-25-025491.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1401914/000149315225025491/0001493152-25-025491-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1401914/000149315225025491/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T15:52:06.976551+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}